Our results show that in CNS WHO grade 1 glioma samples there is no overexpression of SDHB, meanwhile the samples of CNS WHO grade 2 showed an expression level of 1.7 and 5.7-fold, and CNS WHO grade 3 and 4 samples showed overexpression of 2.6 to 7.47-fold. Here, SDHB is linked to central nervous system cancer.